CIRM Funded Clinical Trials

Induction of Tolerance to Combined Kidney and Hematopoietic Progenitor Cell Transplants from HLA Haplotype Matched Living Donors


Samuel Strober
Disease Area: 
Investigator:
CIRM Grant:
Award Value:
$6,653,266
Trial Sponsor:
Stanford University
Trial Stage: 
Phase 1
Trial Status: 
Recruiting
Targeted Enrollment:
15
ClinicalTrials.gov ID:
Details: 

Unmet medical need for allogeneic kidney transplants. Need to eliminate chronic rejection/allograft nephropathy that causes gradual loss of kidney (50% of graft loss by 12-15 years in HLA mismatched recipients). Eliminate the lifelong need for anti-rejection drugs that have numerous cumulative side effects.

Design: 

Open label, single arm study.

Goal: 

Primary: Safety. Secondary: Preliminary efficacy.

Status: 

Enrolling. Opening additional sites.